Market Research Logo

Achromatopsia - Pipeline Review, H1 2016

Achromatopsia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Achromatopsia - Pipeline Review, H1 2016’, provides an overview of the Achromatopsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Achromatopsia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Achromatopsia
  • The report reviews pipeline therapeutics for Achromatopsia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Achromatopsia therapeutics and enlists all their major and minor projects
  • The report assesses Achromatopsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Achromatopsia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Achromatopsia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Achromatopsia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Achromatopsia Overview
Therapeutics Development
Pipeline Products for Achromatopsia - Overview
Achromatopsia - Therapeutics under Development by Companies
Achromatopsia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Achromatopsia - Products under Development by Companies
Achromatopsia - Companies Involved in Therapeutics Development
Amgen Inc.
Applied Genetic Technologies Corporation
Achromatopsia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Gene Therapy for Achromatopsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for X-linked retinoschisis and Achromatopsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate CNGA3 for Achromatopsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate CNGB3 for Achromatopsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Cone Photoreceptor cGMP-Gated Channel for Achromatopsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Achromatopsia - Recent Pipeline Updates
Achromatopsia - Product Development Milestones
Featured News & Press Releases
Apr 20, 2016: AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia
Jan 07, 2016: AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases
Nov 23, 2015: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia
Nov 02, 2015: AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGB3 Gene
Oct 22, 2015: AGTC Announces Orphan Drug Designation in the European Union for Gene Therapy to Treat Achromatopsia
Aug 27, 2015: AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration
May 18, 2015: AGTC Announces New Data Supporting Novel Gene-Based Therapies for Rare Inherited Retinal Diseases
May 04, 2015: Novel Gene-Based Therapy for Achromatopsia Demonstrates Functional Rescue of Cone Cells
Jul 23, 2013: The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Achromatopsia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Achromatopsia - Pipeline by Amgen Inc., H1 2016
Achromatopsia - Pipeline by Applied Genetic Technologies Corporation, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Achromatopsia Therapeutics - Recent Pipeline Updates, H1 2016
List of Figures
Number of Products under Development for Achromatopsia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report